<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB
[XX] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1997
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ____________________ to ________________________
Commission File Number: 0-26972
________________________________________________________
SWISSRAY International, Inc.
_______________________________________________________________________________
(Exact name of registrant as specified in its charter)
New York 16-0950197
________________________________________________________________________________
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
c/o Gary B. Wolff, P.C., 747 Third Avenue, New York, NY 10017
________________________________________________________________________________
(Address of principal executive offices) (Zip Code)
New York (212) 644-6446 Switzerland 011 41 41 919 90 50
________________________________________________________________________________
(Registrant's telephone number, including area code)
________________________________________________________________________________
(Former name, former address and former fiscal year, if changed since last
report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. [x] Yes [ ] No
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's class of
common stock, as of the latest practicable date.
The number of shares outstanding of each of the registrant's classes of common
stock, as of May 9, 1997 is 18,025,801 shares, all of one class of $.01 par
value common stock.
1
<PAGE> 2
TABLE OF CONTENTS
Page No.
PART I
Item 1. Financial Statements F1-F5
Item 2. Management's Discussion and Analysis
of Financial Condition and Results of
Operations and Plan of Operations 3-7
PART II
Item 1. Legal Proceedings 8
Item 2. Changes in Securities 8
Item 3. Defaults Upon Senior Securities 8
Item 4. Submission of Matters to a
Vote of Security Holders 8
Item 5. Other Information 8
Item 6. Exhibits and Reports on Form 8-K 8
Signatures 9
2
<PAGE> 3
SWISSRAY INTERNATIONAL, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
ASSETS
<TABLE>
<CAPTION>
March 31, June 30,
1997 1996
------------ ------------
<S> <C> <C>
CURRENT ASSETS:
Cash and cash equivalents $ 1,871,230 $ 3,252,685
Accounts receivable, net of allowance for doubtful accounts
of $86,531 (March 1997) and $109,843 (June 1996) 3,477,509 3,335,679
Accounts receivables - affiliates 27,286 31,533
Note receivable -- 962,500
Inventories 6,320,228 2,912,836
Prepaid expenses and sundry receivables 1,418,615 1,075,681
------------ ------------
TOTAL CURRENT ASSETS 13,114,868 11,570,914
------------ ------------
PROPERTY AND EQUIPMENT, at cost, net of accumulated
depreciation of $353,999 (March 1997) and $233,995 (June 1996) 1,187,532 1,138,282
------------ ------------
OTHER ASSETS:
Due from stockholders 13,812 17,414
Due from affiliates 161,531 186,676
Accounts receivable - long-term, net of discount and
allowance for doubtful account of $300,000 787,300 1,038,693
Licensing agreement, net of accumulated amortization of $744,986
(March 1997) and $372,493 (June 1996) 4,221,589 4,594,082
Patents and trademarks, net of accumulated amortization of
$48,824 (March 1997) and $28,001 (June 1996) 234,122 220,018
Organization cost, net of accumulated amortization of $2,210
(March 1997) and $978 (June 1996) 6,175 7,407
Other intangibles, net of accumulated amortization of $61,343 378,958 --
Loan receivable 862,500 --
Interest receivable - long-term 129,957 --
Security deposits 17,313 19,952
------------ ------------
TOTAL OTHER ASSETS 6,813,257 6,084,242
------------ ------------
TOTAL ASSETS $ 21,115,657 $ 18,793,438
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Notes payable, banks $ 1,926,952 $ 2,069,828
Loans payable 2,150,134 667,355
Accounts payable 2,909,707 4,186,092
Accounts payable - affiliates 27,122 1,541
Accrued expenses 1,466,442 1,135,693
Customer deposits 203,604 77,673
------------ ------------
TOTAL CURRENT LIABILITIES 8,683,961 8,138,182
------------ ------------
STOCKHOLDERS' EQUITY:
Common stock, $.01 par value; authorized 30,000,000 shares,
issued and outstanding 17,797,729 shares at March 31, 1997 and
14,185,064 shares at June 30, 1996 177,978 141,851
Additional paid-in capital 25,672,921 19,268,400
Accumulated deficit (11,533,846) (7,918,948)
Cumulative foreign currency translation adjustment (1,885,357) (836,047)
------------ ------------
TOTAL STOCKHOLDERS' EQUITY 12,431,696 10,655,256
------------ ------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 21,115,657 $ 18,793,438
============ ============
</TABLE>
See notes to financial statements.
F-1
<PAGE> 4
SWISSRAY INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
Nine Months Ended Three Months Ended
March 31, March 31,
----------------------------- -----------------------------
1997 1996 1997 1996
------------ ------------ ------------ ------------
<S> <C> <C> <C> <C>
NET SALES $ 9,117,390 $ 7,726,869 $ 3,044,971 $ 1,791,184
COST OF SALES 4,901,693 3,851,582 1,883,445 785,197
------------ ------------ ------------ ------------
GROSS PROFIT 4,215,697 3,875,287 1,161,526 1,005,987
------------ ------------ ------------ ------------
OPERATING EXPENSES:
Officers and directors compensation 388,043 291,214 107,713 79,106
Salaries 1,599,868 1,780,064 491,983 647,341
Selling 869,710 844,137 312,966 230,803
Research and development 2,297,965 819,761 460,132 299,912
General and administrative 1,009,614 903,101 373,361 376,056
Other operating expenses 1,172,798 530,212 296,714 95,880
Bad debts -- 158,245 -- --
Depreciation and amortization 556,648 352,187 200,712 189,372
------------ ------------ ------------ ------------
TOTAL OPERATING EXPENSES 7,894,646 5,678,921 2,243,581 1,918,470
------------ ------------ ------------ ------------
LOSS BEFORE OTHER INCOME
(EXPENSES) AND INCOME TAXES (3,678,949) (1,803,634) (1,082,055) (912,483)
OTHER INCOME (EXPENSES) 64,050 184,226 305,760 60,565
------------ ------------ ------------ ------------
LOSS FROM CONTINUING OPERATIONS
BEFORE INCOME TAXES (3,614,899) (1,619,408) (776,295) (851,918)
INCOME TAX PROVISION -- -- -- --
------------ ------------ ------------ ------------
NET LOSS $ (3,614,899) $ (1,619,408) $ (776,295) $ (851,918)
============ ============ ============ ============
LOSS PER COMMON SHARE $ (.24) $ (.13) $ (.05) $ (.06)
============ ============ ============ ============
WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING 14,769,274 12,669,234 15,685,122 13,235,064
============ ============ ============ ============
</TABLE>
See notes to financial statements.
F-2
<PAGE> 5
SWISSRAY INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
NINE MONTHS ENDED MARCH 31, 1997 AND 1996
(UNAUDITED)
<TABLE>
<CAPTION>
Cumulative
Foreign
Common Stock Additional Currency
----------------------- Paid-in Accumulated Translation
Shares Amount Capital Deficit Adjustment Total
---------- --------- ----------- ------------ ----------- ------------
<S> <C> <C> <C> <C> <C> <C>
BALANCE - July 1, 1995 12,035,064 $ 120,351 $12,719,998 $ (6,027,336) $ (436,180) $ 6,376,833
For the nine months ended March 31, 1996:
Issuance of common stock for cash 1,200,000 12,000 5,198,999 -- -- 5,210,999
Additional paid-in capital -- -- 100,000 -- -- 100,000
Foreign currency translation adjustment -- -- -- -- (330,206) (330,206)
Net loss for the period -- -- -- (1,619,408) -- (1,619,408)
---------- --------- ----------- ------------ ----------- ------------
BALANCE - March 31, 1996 13,235,064 $ 132,351 $18,018,997 $ (7,646,744) $ (766,386) $ 9,738,218
========== ========= =========== ============ =========== ============
BALANCE - July 1, 1996 14,185,064 $ 141,851 $19,268,400 $ (7,918,948) $ (836,047) $ 10,655,256
For the nine months ended March 31, 1997:
Issuance of common stock for cash 3,860,065 38,601 6,372,847 -- -- 6,411,448
Surrender of common stock (278,400) (2,784) 2,784 -- -- --
Options exercised 31,000 310 28,890 -- -- 29,200
Foreign currency translation adjustment -- -- -- -- (1,049,310) (1,049,310)
Net loss for the period -- -- -- (3,614,898) -- (3,614,898)
---------- --------- ----------- ------------ ----------- ------------
BALANCE - March 31, 1997 17,797,729 $ 177,978 $25,672,921 $(11,533,846) $(1,885,357) $ 12,431,696
========== ========= =========== ============ =========== ============
</TABLE>
See notes to financial statements.
F-3
<PAGE> 6
SWISSRAY INTERNATIONAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED MARCH 31, 1997 AND 1996
(UNAUDITED)
<TABLE>
<CAPTION>
1997 1996
----------- -----------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(3,614,899) $(1,619,408)
Adjustment to reconcile net loss to net cash from operating activities:
Depreciation and amortization 556,649 352,187
Provision for bad debts (23,312) --
Foreign currency translation (1,074,644) 14,678
(Increase) decrease in operating assets:
Accounts receivable 137,122 (1,346,123)
Inventories (3,407,392) (2,269,597)
Prepaid expenses and sundry receivables (472,891) (212,728)
Security deposits 2,639 --
Increase (decrease) in operating liabilities:
Accounts payable (1,250,804) 723,540
Accrued expenses 330,749 486,904
Customer deposits 125,931 141,660
----------- -----------
NET CASH USED BY OPERATING ACTIVITIES (8,690,852) (3,728,887)
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment (169,254) (448,361)
Patents and trademarks (34,927) (31,463)
Other intangibles (378,958) --
Collection of notes receivable 100,000 --
Repayments from affiliates 25,145 2,383
----------- -----------
NET CASH USED BY INVESTING ACTIVITIES (457,994) (477,441)
----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term borrowing 3,943,887 500,549
Principal payments of short-term borrowings (2,092,883) (1,007,572)
Principal payments of long-term borrowing (511,101) (15,146)
Issuance of common stock for cash 6,440,648 5,310,999
Repayment from (advances to) stockholder 3,602 (151,132)
Advances to officer -- 4,354
----------- -----------
NET CASH PROVIDED BY FINANCING ACTIVITIES 7,784,153 4,642,052
----------- -----------
EFFECT OF EXCHANGE RATE CHANGES ON CASH (16,762) (344,884)
----------- -----------
NET INCREASE (DECREASE) IN CASH (1,381,455) 90,840
CASH AND CASH EQUIVALENTS - beginning of period 3,252,685 2,676,826
----------- -----------
CASH AND CASH EQUIVALENTS - end of period $ 1,871,230 $ 2,767,666
=========== ===========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest $ 171,416 $ 166,064
=========== ===========
</TABLE>
See notes to financial statements.
F-4
<PAGE> 7
SWISSRAY INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 1997
NOTE 1 - BASIS OF PRESENTATION
The accompanying unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles
for interim financial information and with the instructions to Form
10-Q and Article 10 of Regulation S-X. Accordingly, they do not include
all of the information and footnotes required by generally accepted
accounting principles for complete financial statements. In the opinion
of management, all adjustments (consisting of normal recurring
accruals) considered necessary for a fair presentation have been
included. Operating results for the nine month period ended March 31,
1997 are not necessarily indicative of the results that may be expected
for the year ending June 30, 1997. The unaudited consolidated financial
statements should be read in conjunction with the consolidated
financial statements and footnotes thereto included in the Company's
Form 10-KSB for the year ended June 30, 1996.
NOTE 2 - SUBSEQUENT EVENT
On April 1, 1997 the Company acquired all of the issued and outstanding
securities of Empower Inc., a Glen Cove, New York based distributor of
X-Ray equipment and medical supplies. The acquisition was reported on
Form 8-K and filed with the Securities and Exchange Commission on April
15, 1997.
F-5
<PAGE> 8
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS
Background Summary
The Company acquired it wholly owned subsidiary, SR-Medical AG, in June
of 1995 in exchange for 7,000,000 shares of its common stock. The merger between
the Company and SR-Medical AG is considered for accounting purposes to be a
recapitalization of SR-Medical AG with SR-Medical AG as the acquirer. The
unaudited consolidated financial statements for all periods presented take into
account SWISSRAY International, Inc. - the Parent - as well as SR-Medical AG,
Teleray AG, SR-Medical GmbH and SR Finance AG., while the consolidated financial
statements for the nine month period ended March 31, 1997 and for the three
month period ended March 31, 1997 also take into account the accounts of
Swissray Corporation, a wholly owned subsidiary formed under the laws of the
State of Delaware in November 1996, which firm commenced operations in January
1997).
This discussion summarizes the significant factors affecting the
consolidated operating results, financial condition and liquidity/cash flows of
the Company as at quarter ended March 31, 1997 and year ended June 30, 1996 with
respect to the Company's consolidated balance sheets and the comparative three
month periods ended March 31, 1997 and March 31, 1996 (as well as the
comparative nine month periods ended March 31, 1997 and March 31, 1996) based
upon information appearing in the Company's consolidated statements of
operations and related financial statements and should be read in conjunction
with such unaudited consolidated financial statements.
The Company, operating through its subsidiaries (i.e., its wholly owned
subsidiary, SR-Medical AG, and the latter's wholly owned subsidiaries, Teleray
AG (a Swiss corporation) and SR-Medical GmbH (a German corporation), as well as
through the Company's wholly owned subsidiaries, SR Finance AG, (a Swiss
corporation) and Swissray Corporation (a Delaware corporation) remains engaged
in the diagnostic X-ray medical equipment market, wherein it develops, assembles
and sells worldwide, both directly and indirectly under its label SWISSRAY as
well as to Original Equipment Manufacturers (OEM) partners, X-ray units and
accessories. Recently, substantial efforts have been concentrated upon its newly
developed digital imaging processing system called "SwissVision" designed to
enhance X-ray diagnosis with computer assistance by (integrating computer
technology with radiology in order to support the radiologist in diagnostic
functions) utilizing a Digital, relatively recently developed, "Add-on" Bucky
which allows for direct digitalization of the radiology process (and eliminates
the need for the use and subsequent storage and/or retrieval of X-ray film). In
that respect and as heretofore indicated in the Company's Form 10-KSB the
Company had expended during fiscal year ended June 30, 1996, in excess of
$1,700,000 for research and development expenditures, which expenditures
accounted for approximately 20% of all operating expenses during fiscal year
ended June 30, 1996. The Company's research and development expenditures during
the quarter ended March 31, 1997 amounted to $460,132 or approximately 21% of
all operating expenses during such quarter as compared to research and
development expenditures of $299,912 or approximately 16% of all operating
expenses for the quarter ended March 31, 1996. Further, the Company's research
and development expenditures during the nine month period ended March 31, 1997
amounted to $2,297,965 or approximately 29% of all operating expenses during
such nine
3
<PAGE> 9
month period (as compared to research and development expenditures of $819,761
or approximately 14% of all operating expenses incurred during the comparative
nine month period ended March 31, 1996). Management considers its research and
development expenditures (which have been by far the significant largest
operating expense of the Company during the nine month period ended March 31,
1997) to be a integral and necessary expenditure in order to enhance the
Company's competitive edge and continuously develop its advanced technological
products within the diagnostic x-ray medical equipment industry and in
particular within the digitalization of the radiology processes.
Consolidated Statements of Operations for the Comparative Nine month Periods
Ended March 31, 1997 and March 31, 1996
Net sales for the nine month period ended March 31, 1997 were $9,117,390
as compared to net sales of $7,726,869 for the comparative nine month period
ended March 31, 1996, while cost of sales increased for the comparative nine
month period ended March 31, 1996 from $3,851,582 to $4,901,693 (for the nine
month period ended March 31, 1997) resulting in a gross profit for the nine
month period ended March 31, 1997 of $4,215,697 (representing approximately 46%
of net sales) as compared to $3,875,287 for the comparative nine month period
ended March 31, 1996 (representing approximately 50% of net sales). Accordingly,
gross profits for the comparative nine month periods increased by $340,410 (an
increase of approximately 9% from the comparative nine month period ended March
31, 1996). Operating expenses increased by $2,215,725 (from $5,678,921 to
$7,894,646) during the comparative nine month periods with the two largest items
of operating expenses during the nine month period ended March 31, 1997 being
represented by (a) the aggregate of officers and directors compensation and
salaries which represented approximately 25% of all such operating expenses (as
compared to representing 36% of operating expenses for the nine month period
ended March 31, 1996) and (b) research and development which represented
approximately 29% of all such operating expenses (as compared to representing
14% of operating expenses for the nine month period ended March 31, 1996).
Primarily as a result of the above, net losses increased from $(1,619,408) for
the nine month period ended March 31, 1996 to $(3,614,899) for the nine month
period ended March 31, 1997; an increase in net losses of $1,995,491 - (an
approximate increase of approximately 123% in net losses) which increase in net
loss may be principally attributed to the $1,478,204 increase in research and
development expenditures during the comparative nine month period ended March
31, 1997.
Consolidated Statements of Operations for the Comparative Three Month Periods
Ended March 31, 1997 and March 31, 1996
Net sales for the three month period ended March 31, 1997 were
$3,044,971 as compared to net sales of $1,791,184 for the comparative three
month period ended March 31, 1996, while cost of sales increased for the
comparative three month period ended March 31, 1996 from $785,197 to $1,883,445
(for the three month period ended March 31, 1997) resulting in a gross profit
for the three month period ended March 31, 1997 of $1,161,526 (representing
approximately 38% of net sales) as compared to $1,005,987 for the comparative
three month period ended March 31, 1996 (representing approximately 56% of net
sales). Accordingly, gross profits for the comparative three
4
<PAGE> 10
month periods increased by $155,539 (an increase of approximately 15% from the
comparative three month period ended March 31, 1996). Operating expenses
increased by $325,111 (from $1,918,470 to $2,243,581) during the comparative
three month periods with the two largest items of operating expenses during the
three month period ended March 31, 1997 being represented by (a) the aggregate
of officers and directors compensation and salaries which represented
approximately 27% of all such operating expenses (as compared to representing
38% of operating expenses for the three month period ended March 31, 1996) and
(b) research and development which represented approximately 21% of all such
operating expenses (as compared to representing 16% of operating expenses for
the three month period ended March 31, 1996). Primarily as a result of the
above, net losses decreased from $(851,918) for the three month period ended
March 31, 1996 to $(776,295) for the three month period ended March 31, 1997; a
decrease in net losses of $75,623 - (an approximate decrease of approximately 9%
in net losses) which decrease in net loss may be principally attributed to the
$126,751 decrease in the aggregate of officers and directors compensation and
salaries during the comparative three month period ended March 31, 1997.
Consolidated Balance Sheets
Total assets of the Company at the three month period ended March 31,
1997 and fiscal year ended June 30, 1996 were $21,115,657 and $18,793,438
respectively; a increase of $2,322,219, with total current assets increasing
from $11,570,914 at June 30, 1996 to $13,114,868 at March 31, 1997 - an increase
of $1,543,954. The increase in total current assets is primarily attributable to
increases in accounts receivable ($141,830), inventories ($3,407,392) and
prepaid expense and sundry receivable (342,934) - an aggregate increase of
$3,892,156 - offset principally by decreases in cash and cash equivalents
($1,381,455) and notes receivable ($962,500) - an aggregate decrease of
$2,343,955.
Total current liabilities of the Company at the three month period ended
March 31, 1997 and fiscal year ended June 30, 1996 were $8,683,961 and
$8,138,182 respectively, an increase of $545,779.
At March 31, 1997 there were no long term liabilities.
Working capital at March 31, 1997 was $4,430,907 as compared to working
capital of $3,432,732 at June 30, 1996; an increase of $998,175 (as a result of
the aforesaid increase of $1,543,954 in total current assets and an increase of
$545,779 in total current liabilities).
Total stockholders' equity of the Company at the three month period
ending March 31, 1997 and the fiscal year ended June 30, 1996 were $12,431,696
and $10,655,256 respectively, an increase of $1,776,440.
The functional currencies of SR Medical AG, Teleray AG and SR Finance AG
(Swiss corporations) are Swiss Francs while the functional currency of SR
Medical GmbH (a German corporation) is German Marks. Gains and losses resulting
from foreign currency transactions which
5
<PAGE> 11
are included in operations have been insignificant for all periods reported.
However, the effects of exchange rate fluctuations on translating foreign
currency assets and liabilities and results of operations from functional
currency to Unites States dollars has been significant with the cumulative
foreign currency translation adjustment (loss) to stockholders' equity
increasing from $(836,047) at June 30, 1996 to $(1,885,357) at March 31, 1997
(an increase of $1,049,310). The foregoing was a direct result of the U.S.
dollar becoming stronger against both Swiss Francs and German Marks.
Discussion and Analysis
As heretofore disclosed in Form 8-K with date of report of January 10,
1997 (filed January 23, 1997), the Company issued convertible debentures for
aggregate gross principal of $3,500,000, which debentures were convertible into
shares of Company common stock at 81% of average bid price for the five trading
days preceding date of conversion. All conversions were completed as of May 6,
1997 resulting in the issuance of 2,395,701 shares of Company common stock to
debenture holders.
Further and as heretofore indicated in Form 8-K with date of report of
March 5, 1997 (filed March 18, 1997) the Company issued 1,000,000 shares of its
common stock (pursuant to Off-Shore Securities Subscription Agreement in
accordance with Regulation S under the Securities Act of 1933) for gross
proceeds of $2,000,000.
It is anticipated that substantial portions of the net proceeds received
from the above referenced financings will be utilized by the Company for its
continuous and ongoing research and development program, primarily with respect
to its Digital AddOn System which utilizes the Company's AddOn Bucky for direct
and cassettless digital acquisition of x-ray information.
Approximately $2,300,000 has been invested in research and development
during the nine month period ended March 31, 1997. Such expenditures relate
principally to the following products:
1. Swiss Vision, a digital image processing system compatible with modern
x-ray units.
2. Digital AddOn Bucky, an input device allowing for direct digitalization
of x-ray images.
3. Digital AddOn System, a fully digital multifunctional x-ray system using
AddOn Bucky and a new mobile patient table with floating top. All
movements are radio controlled.
4. Bucky Diagnost TS, a ergonomically designed conventional x-ray unit with
a state of the art generator.
In the Company's Form 10-QSB for its quarter ended December 31, 1996 it
reported that it had entered into an agreement in November 1996 to acquire all
of the issued and outstanding securities of Empower Inc., a company engaged in
the x-ray business and operating primarily in the tri-state (New York, New
Jersey and Connecticut) area and further reported that it anticipated closing of
such transaction during the Company's third fiscal quarter. Such transaction
became effective April 1, 1997 and a brief summary of certain of the relevant
terms and conditions thereof were contained in the Company's Form 8-K with date
of report of April 1, 1997 (filed April 15, 1997).
6
<PAGE> 12
Annual Meeting
During the third quarter of the Company's fiscal year and in particular
on March 7, 1997 the Company held its Annual Meeting of Stockholders in New
York, New York, at which time (in addition to the election of former Board
members) Company stockholders elected Ueli Laupper to serve on the Company's
Board. Mr. Ueli Laupper heads the marketing and sales department and is
responsible for reporting marketing expectations to the Board. Subsequent to the
Annual Meeting, a Special Meeting of the Board was held at which time Mr. Ruedi
G. Laupper was elected Chairman of the Board while continuing to maintain the
position of President of the Company.
During the Annual Meeting, shareholders approved the increase in the
number of authorized shares of Company common stock from 15,000,000 to
30,000,000 shares. Management of the Company considered such authorization to be
quite important to assure the future growth and/or financing and/or acquisition
program (if and when necessary and advisable) of the Company.
Additional Recent Developments
In early February 1997, the State of Slovakia invited Company
representatives to the public ceremony for the opening of the first three x-ray
rooms which were outfitted with Company equipment. Deliveries and installations
for this order from the Swiss government are ongoing.
In early March 1997, Company representatives attended the ECR radiology
congress in Vienna, Austria, for further presentation of its Digital AddOn
System. Prospective buyers especially from Eastern European and Asian countries
were quite numerous and expressed substantial interest in both the Company's
digital x-ray and its conventional x-ray equipment.
During March 1997, the first two units of Bucky Diagnost TS (state of
the art conventional x-ray equipment fully developed by the Company) were
delivered and this is the second product (besides the MRS system) which is part
of the multimillion dollar Original Equipment Manufacturing ("OEM") contract
with Philips. Incoming orders and forecasts for the period through December 31,
1997 appear promising. Additionally, forecasts for deliveries of MRS x-ray units
under the aforesaid OEM Agreement with Philips indicate numbers which should
permit the Company to expedite shipments and resolve delays heretofore incurred.
Management considers its relationship with Philips to be quite satisfactory and
mutually rewarding and is pleased to indicate that Philips has demonstrated its
satisfaction with the Company and its products by inviting the Company as a key
supplier, to Philips "Customer Day" held in Hamburg, Germany.
Against what management of the Company considered to be substantial
competition the Company was awarded two contracts with hospitals located in
Montreux and Aigle (Switzerland) to supply such hospitals with two Computer
Tomography Systems of the "CT Twin Flash" type with Omnipro Workstation with
total estimated billings U.S.$1,100,000. The deliveries of these two units are
expected to be completed in May 1997.
As of April 1, 1997 Dr. med. Felix Riedel entered the Company's
management team. Dr. med. Riedel is a medical specialist in radiology and
nuclear medicine with his principal responsibilities being in the following
areas: participation in all kinds of development (especially digital x-ray
technologies), product management and publication of academic reports and
product-related reports. Dr. med. Riedel's employment signifies an increase in
the strength of Company management on both the academic and scientific sides.
7
<PAGE> 13
PART II
Item 1. Legal Proceedings - *
Item 2. Changes in Securities - (1)
Item 3. Defaults Upon Senior Securities - None
Item 4. Submission of Matters to a
Vote of Security Holders - (2)
Item 5. Other Information - None
Item 6. Exhibits and Reports on Form 8-K - as follows:
Form 8-K with date of report January 10, 1997 - filed January 23,
1997 Form 8-K with date of report March 5, 1997 - filed March 18,
1997
* Reference is herewith made to Form 10-KSB for fiscal year ended June 30,
1996 and financial statements included therein and in particular to Part
I, Item 3 and Note 27 to the consolidated financial statements, the full
contents of which are herewith incorporated by reference in accordance
with Rule 12b-23 of the General Rules and Regulations under the
Securities Exchange Act of 1934.
(1) Increase in authorized shares of common stock from 15,000,000 to
30,000,000 in accordance with stockholder approval at March 7, 1997
Annual Meeting of Stockholders.
(2) At the Company's aforesaid Annual Meeting of Stockholders principal
matters that were submitted for stockholders' vote related to (a) the
aforesaid increase in authorized shares, (b) the heretofore indicated
nomination and election of Company Board of Directors and (c) the
appointment of Bederson & Company LLP as independent auditors of the
Company for fiscal year ending June 30, 1997.
8
<PAGE> 14
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
SWISSRAY INTERNATIONAL, INC.
/Josef Laupper/
By______________________________
Josef Laupper, Secretary
Dated: May 13 , 1997
9
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM BALANCE
SHEET, (B) STATEMENT OF OPERATIONS AND IS QUALIFIED IN ITS INTIRETY BY REFERENCE
TO SUCH.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> JUN-30-1996
<PERIOD-START> JUL-01-1997
<PERIOD-END> MAR-31-1997
<CASH> 1871230
<SECURITIES> 0
<RECEIVABLES> 3591326
<ALLOWANCES> 86531
<INVENTORY> 6320228
<CURRENT-ASSETS> 13114868
<PP&E> 1541531
<DEPRECIATION> 353999
<TOTAL-ASSETS> 21115657
<CURRENT-LIABILITIES> 8683961
<BONDS> 0
177978
0
<COMMON> 0
<OTHER-SE> 12253718
<TOTAL-LIABILITY-AND-EQUITY> 21115657
<SALES> 9117390
<TOTAL-REVENUES> 9117390
<CGS> 4901693
<TOTAL-COSTS> 4901693
<OTHER-EXPENSES> 7894646
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 171416
<INCOME-PRETAX> (3614899)
<INCOME-TAX> 0
<INCOME-CONTINUING> (3614899)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (3614899)
<EPS-PRIMARY> (.24)
<EPS-DILUTED> (.24)
</TABLE>
